Published on 27 Dec 2021 on Zacks via Yahoo Finance
Laboratory Corporation of America Holdings LH or LabCorp entered a definitive agreement to acquire Personal Genome Diagnostics (“PGDx”) — a leader in cancer genomics with a portfolio of wide-ranging liquid biopsy and tissue-based products. The acquisition of PGDx is the newest development in LabCorp’s long-standing commitment to incorporate precision medicine into its comprehensive offering of oncology solutions.
It is worth mentioning that next-generation sequencing (NGS), including liquid biopsy, represents the future of treatment and response monitoring in people suffering from cancer. Liquid biopsy testing can also eliminate the need for an invasive biopsy procedure, reducing costs and improving patient outcomes. With more cancer patients gaining access to NGS testing, LabCorp will be able to offer enriched, actionable and data-driven insights.
Financial Details